Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Research Council grant · Running

UNIINK Universal 3D printer bioink for Type 1 diabetes cell therapy

Coordinator
Fundacio Institut De Bioenginyeria De Catalunya, Spain
Runs
1 January 2024 to 30 June 2025
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101113301

What the project is doing

In the project's own words, from its summary on CORDIS.

Type 1 Diabetes (T1DM) results from autoimmune destruction of pancreatic insulin-producing -cells. Nowadays, insulin injections remain the leading therapeutic option. However, injection treatment fails to emulate the highly dynamic insulin release that -cells provide. During the last years, 3D cell-laden microspheres have been proposed as a major platform for bioengineering insulin-secreting constructs for tissue graft implantation and a model for in vitro drug screening platforms.

Current microsphere fabrication technologies have several drawbacks: the need for an oil phase containing surfactants, diameter inconsistency of the microspheres, and high time-consuming processes, among others. These technologies have widely used alginate for its rapid gelation, high processability, and low cost. However, its low biocompatible properties do not provide effective cell attachment. To overcome these limitations, Uniink proposes a high-throughput 3D bioprinting methodology that employs an ECM-like microenvironment for effective cell-laden microsphere production.

Crosslinking the resulting microspheres with tannic acid (TA) prevents collagenase degradation and enhances spherical structural consistency while allowing the diffusion of nutrients and oxygen. In addition, the approach allows customization of microsphere diameter with extremely low variability. In conclusion, we will develop in Uniink a novel bio-printing procedure to fabricate large amounts of reproducible microspheres capable of secreting insulin in response to extracellular glucose stimuli.

We expect that Uniink will represent a valid alternative to islet transplantation in T1DM patients, thus bringing cell therapy closer to the application in humans.

Topics

Who is involved

OrganisationCityCountryRole
Fundacio Institut De Bioenginyeria De CatalunyaBarcelonaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI